RhoGDI signaling provides targets for cancer therapy

European Journal of Cancer

Volumn 46, Issue 7, 2010, Pages 1252-1259

  Harding, Michael A ^a   Theodorescu, Dan ^a  

^a UNIVERSITY OF VIRGINIA   (United States)

Author keywords

Angiogenesis; Bladder cancer; Breast cancer; Cancer therapy; Guanine Nucleotide Dissociation Inhibitors; Pancreatic cancer; RhoGDI1; RhoGDI2; RhoGDIs; RhoGTPase

Indexed keywords

ATRASENTAN; CISPLATIN; ENDOTHELIN 1; GEMCITABINE; GUANINE NUCLEOTIDE DISSOCIATION INHIBITOR; GUANOSINE TRIPHOSPHATASE; N (3 METHOXY 5 METHYL 2 PYRAZINYL) 2 [4 (1,3,4 OXADIAZOL 2 YL)PHENYL] 3 PYRIDINESULFONAMIDE; NEUROMEDIN U; RHO FACTOR;

ARTICLE; BLADDER CANCER; BONE METASTASIS; BREAST CANCER; CANCER CELL CULTURE; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER PATIENT; CANCER SURVIVAL; CARCINOGENESIS; DISEASE FREE SURVIVAL; DRUG SAFETY; DRUG TOLERABILITY; ENDOTHELIUM CELL; HUMAN; LUNG METASTASIS; MULTIPLE CYCLE TREATMENT; NONHUMAN; OVERALL SURVIVAL; PANCREAS CANCER; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; PROTEIN EXPRESSION; PROTEIN FAMILY; SIGNAL TRANSDUCTION;

ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; FEMALE; GUANINE NUCLEOTIDE DISSOCIATION INHIBITORS; HUMANS; NEOPLASM PROTEINS; NEOPLASMS; PANCREATIC NEOPLASMS; SIGNAL TRANSDUCTION; URINARY BLADDER NEOPLASMS;

EID: 77950595288     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejca.2010.02.025     Document Type: Article

References (61)

1. Lu Q., Longo F.M., Zhou H., Massa S.M., and Chen Y.H. Signaling through Rho GTPase pathway as viable drug target. Curr Med Chem 16 11 (2009) 1355-1365
2. Oxford G., and Theodorescu D. Ras superfamily monomeric G proteins in carcinoma cell motility. Cancer Lett 189 2 (2003) 117-128
3. DerMardirossian C., and Bokoch G.M. GDIs: central regulatory molecules in Rho GTPase activation. Trends Cell Biol 15 7 (2005) 356-363
4. Dovas A., and Couchman J.R. RhoGDI: multiple functions in the regulation of Rho family GTPase activities. Biochem J 390 Pt 1 (2005) 1-9
5. Dransart E., Olofsson B., and Cherfils J. RhoGDIs revisited: novel roles in Rho regulation. Traffic 6 11 (2005) 957-966
6. Dransart E., Morin A., Cherfils J., and Olofsson B. RhoGDI-3, a promising system to investigate the regulatory function of rhoGDIs: uncoupling of inhibitory and shuttling functions of rhoGDIs. Biochem Soc Trans 33 Pt 4 (2005) 623-626
7. Karlsson R., Pedersen E.D., Wang Z., and Brakebusch C. Rho GTPase function in tumorigenesis. Biochim Biophys Acta 1796 2 (2009) 91-98
8. Vega F.M., and Ridley A.J. Rho GTPases in cancer cell biology. FEBS Lett 582 14 (2008) 2093-2101
9. Johnson J.L., Erickson J.W., and Cerione R.A. New insights into how the Rho guanine nucleotide dissociation inhibitor regulates the interaction of Cdc42 with membranes. J Biol Chem 284 35 (2009) 23860-23871
10. Lin Q., Fuji R.N., Yang W., and Cerione R.A. RhoGDI is required for Cdc42-mediated cellular transformation. Curr Biol 13 17 (2003) 1469-1479
11. Gorvel J.P., Chang T.C., Boretto J., Azuma T., and Chavrier P. Differential properties of D4/LyGDI versus RhoGDI: phosphorylation and rho GTPase selectivity. FEBS Lett 422 2 (1998) 269-273
12. Lelias J.M., Adra C.N., Wulf G.M., Guillemot J.C., Khagad M., Caput D., et al. CDNA cloning of a human mRNA preferentially expressed in hematopoietic cells and with homology to a GDP-dissociation inhibitor for the rho GTP-binding proteins. Proc Natl Acad Sci USA 90 4 (1993) 1479-1483
13. Elfenbein A., Rhodes J.M., Meller J., Schwartz M.A., Matsuda M., and Simons M. Suppression of RhoG activity is mediated by a syndecan 4-synectin-RhoGDI1 complex and is reversed by PKCalpha in a Rac1 activation pathway. J Cell Biol 186 1 (2009) 75-83
14. Knezevic N., Roy A., Timblin B., Konstantoulaki M., Sharma T., Malik A.B., et al. GDI-1 phosphorylation switch at serine 96 induces RhoA activation and increased endothelial permeability. Mol Cell Biol 27 18 (2007) 6323-6333
15. Mehta D., Rahman A., and Malik A.B. Protein kinase C-alpha signals rho-guanine nucleotide dissociation inhibitor phosphorylation and rho activation and regulates the endothelial cell barrier function. J Biol Chem 276 25 (2001) 22614-22620
16. DerMardirossian C., Schnelzer A., and Bokoch G.M. Phosphorylation of RhoGDI by Pak1 mediates dissociation of Rac GTPase. Mol Cell 15 1 (2004) 117-127
17. Togawa A., Miyoshi J., Ishizaki H., Tanaka M., Takakura A., Nishioka H., et al. Progressive impairment of kidneys and reproductive organs in mice lacking Rho GDIalpha. Oncogene 18 39 (1999) 5373-5380
18. Guillemot J.C., Kruskal B.A., Adra C.N., Zhu S., Ko J.L., Burch P., et al. Targeted disruption of guanosine diphosphate-dissociation inhibitor for Rho-related proteins, GDID4: normal hematopoietic differentiation but subtle defect in superoxide production by macrophages derived from in vitro embryonal stem cell differentiation. Blood 88 7 (1996) 2722-2731
19. Yin L., Schwartzberg P., Scharton-Kersten T.M., Staudt L., and Lenardo M. Immune responses in mice deficient in Ly-GDI, a lymphoid-specific regulator of Rho GTPases. Mol Immunol 34 6 (1997) 481-491
20. Koide N., Yamada T., Shibata R., Mori T., Fukuma M., Yamazaki K., et al. Establishment of perineural invasion models and analysis of gene expression revealed an invariant chain (CD74) as a possible molecule involved in perineural invasion in pancreatic cancer. Clin Cancer Res 12 8 (2006) 2419-2426
21. Abiatari I., DeOliveira T., Kerkadze V., Schwager C., Esposito I., Giese N.A., et al. Consensus transcriptome signature of perineural invasion in pancreatic carcinoma. Mol Cancer Ther 8 6 (2009) 1494-1504
22. Katzav S. Flesh and blood: the story of Vav1, a gene that signals in hematopoietic cells but can be transforming in human malignancies. Cancer Lett 255 2 (2007) 241-254
23. Groysman M., Hornstein I., Alcover A., and Katzav S. Vav1 and Ly-GDI two regulators of Rho GTPases, function cooperatively as signal transducers in T cell antigen receptor-induced pathways. J Biol Chem 277 51 (2002) 50121-50130
24. Groysman M., Russek C.S., and Katzav S. Vav, a GDP/GTP nucleotide exchange factor, interacts with GDIs, proteins that inhibit GDP/GTP dissociation. FEBS Lett 467 1 (2000) 75-80
25. Denicola G., and Tuveson D.A. VAV1: a new target in pancreatic cancer?. Cancer Biol Ther 4 5 (2005) 509-511
26. Fernandez-Zapico M.E., Gonzalez-Paz N.C., Weiss E., Savoy D.N., Molina J.R., Fonseca R., et al. Ectopic expression of VAV1 reveals an unexpected role in pancreatic cancer tumorigenesis. Cancer Cell 7 1 (2005) 39-49
27. Katzav S. Vav1: a hematopoietic signal transduction molecule involved in human malignancies. Int J Biochem Cell Biol 41 6 (2009) 1245-1248
28. Li Z., Chang Z., Chiao L.J., Kang Y., Xia Q., Zhu C., et al. TrkBT1 induces liver metastasis of pancreatic cancer cells by sequestering Rho GDP dissociation inhibitor and promoting RhoA activation. Cancer Res 69 19 (2009) 7851-7859
29. Ohira K., Kumanogoh H., Sahara Y., Homma K.J., Hirai H., Nakamura S., et al. A truncated tropomyosin-related kinase B receptor, T1, regulates glial cell morphology via Rho GDP dissociation inhibitor 1. J Neurosci 25 6 (2005) 1343-1353
30. Yamashita T., and Tohyama M. The p75 receptor acts as a displacement factor that releases Rho from Rho-GDI. Nat Neurosci 6 5 (2003) 461-467
31. Fritz G., Brachetti C., Bahlmann F., Schmidt M., and Kaina B. Rho GTPases in human breast tumours: expression and mutation analyses and correlation with clinical parameters. Br J Cancer 87 6 (2002) 635-644
32. Jiang W.G., Watkins G., Lane J., Cunnick G.H., Douglas-Jones A., Mokbel K., et al. Prognostic value of rho GTPases and rho guanine nucleotide dissociation inhibitors in human breast cancers. Clin Cancer Res 9 17 (2003) 6432-6440
33. Hu L.D., Zou H.F., Zhan S.X., and Cao K.M. Biphasic expression of RhoGDI2 in the progression of breast cancer and its negative relation with lymph node metastasis. Oncol Rep 17 6 (2007) 1383-1389
34. Schnelzer A., Prechtel D., Knaus U., Dehne K., Gerhard M., Graeff H., et al. Rac1 in human breast cancer: overexpression, mutation analysis, and characterization of a new isoform, Rac1b. Oncogene 19 26 (2000) 3013-3020
35. Matos P., Collard J.G., and Jordan P. Tumor-related alternatively spliced Rac1b is not regulated by Rho-GDP dissociation inhibitors and exhibits selective downstream signaling. J Biol Chem 278 50 (2003) 50442-50448
36. Singh A., Karnoub A.E., Palmby T.R., Lengyel E., Sondek J., and Der C.J. Rac1b, a tumor associated, constitutively active Rac1 splice variant, promotes cellular transformation. Oncogene 23 58 (2004) 9369-9380
37. Schunke D., Span P., Ronneburg H., Dittmer A., Vetter M., Holzhausen H.J., et al. Cyclooxygenase-2 is a target gene of rho GDP dissociation inhibitor beta in breast cancer cells. Cancer Res 67 22 (2007) 10694-10702
38. Wang Y., Klijn J.G., Zhang Y., Sieuwerts A.M., Look M.P., Yang F., et al. Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer. Lancet 365 9460 (2005) 671-679
39. Foekens J.A., Atkins D., Zhang Y., Sweep F.C., Harbeck N., Paradiso A., et al. Multicenter validation of a gene expression-based prognostic signature in lymph node-negative primary breast cancer. J Clin Oncol 24 11 (2006) 1665-1671
40. Desmedt C., Piette F., Loi S., Wang Y., Lallemand F., Haibe-Kains B., et al. Strong time dependence of the 76-gene prognostic signature for node-negative breast cancer patients in the TRANSBIG multicenter independent validation series. Clin Cancer Res 13 11 (2007) 3207-3214
41. Su L.F., Knoblauch R., and Garabedian M.J. Rho GTPases as modulators of the estrogen receptor transcriptional response. J Biol Chem 276 5 (2001) 3231-3237
42. Su L.F., Wang Z., and Garabedian M.J. Regulation of GRIP1 and CBP Coactivator activity by Rho GDI modulates estrogen receptor transcriptional enhancement. J Biol Chem 277 40 (2002) 37037-37044
43. El Marzouk S., Schultz-Norton J.R., Likhite V.S., McLeod I.X., Yates J.R., and Nardulli A.M. Rho GDP dissociation inhibitor alpha interacts with estrogen receptor alpha and influences estrogen responsiveness. J Mol Endocrinol 39 4 (2007) 249-259
44. Zhang B., Zhang Y., Dagher M.C., and Shacter E. Rho GDP dissociation inhibitor protects cancer cells against drug-induced apoptosis. Cancer Res 65 14 (2005) 6054-6062
45. Reimer J., Bien S., Sonnemann J., Beck J.F., Wieland T., Kroemer H.K., et al. Reduced expression of Rho guanine nucleotide dissociation inhibitor-alpha modulates the cytotoxic effect of busulfan in HEK293 cells. Anticancer Drugs 18 3 (2007) 333-340
46. Harding M.A., and Theodorescu D. RhoGDI2: a new metastasis suppressor gene: discovery and clinical translation. Urol Oncol 25 5 (2007) 401-406
47. Seraj M.J., Harding M.A., Gildea J.J., Welch D.R., and Theodorescu D. The relationship of BRMS1 and RhoGDI2 gene expression to metastatic potential in lineage related human bladder cancer cell lines. Clin Exp Metastasis 18 6 (2000) 519-525
48. Theodorescu D., Sapinoso L.M., Conaway M.R., Oxford G., Hampton G.M., and Frierson Jr. H.F. Reduced expression of metastasis suppressor RhoGDI2 is associated with decreased survival for patients with bladder cancer. Clin Cancer Res 10 11 (2004) 3800-3806
49. Wu Y., Moissoglu K., Wang H., Wang X., Frierson H.F., Schwartz M.A., et al. Src phosphorylation of RhoGDI2 regulates its metastasis suppressor function. Proc Natl Acad Sci U S A 106 14 (2009) 5807-5812
50. DerMardirossian C., Rocklin G., Seo J.Y., and Bokoch G.M. Phosphorylation of RhoGDI by Src regulates Rho GTPase binding and cytosol-membrane cycling. Mol Biol Cell 17 11 (2006) 4760-4768
51. Moissoglu K., McRoberts K.S., Meier J.A., Theodorescu D., and Schwartz M.A. Rho GDP dissociation inhibitor 2 suppresses metastasis via unconventional regulation of RhoGTPases. Cancer Res 69 7 (2009) 2838-2844
52. Titus B., Frierson Jr. H.F., Conaway M., Ching K., Guise T., Chirgwin J., et al. Endothelin axis is a target of the lung metastasis suppressor gene RhoGDI2. Cancer Res 65 16 (2005) 7320-7327
53. Wu Y., McRoberts K., Berr S.S., Frierson Jr. H.F., Conaway M., and Theodorescu D. Neuromedin U is regulated by the metastasis suppressor RhoGDI2 and is a novel promoter of tumor formation, lung metastasis and cancer cachexia. Oncogene 26 5 (2007) 765-773
54. Brighton P.J., Szekeres P.G., and Willars G.B. Neuromedin U and its receptors: structure, function, and physiological roles. Pharmacol Rev 56 2 (2004) 231-248
55. Nelson J., Bagnato A., Battistini B., and Nisen P. The endothelin axis: emerging role in cancer. Nat Rev Cancer 3 2 (2003) 110-116
56. Liu J.J., Payza K., Huang J., Liu R., Chen T., Coupal M., et al. Discovery and pharmacological characterization of a small-molecule antagonist at neuromedin U receptor NMUR2. J Pharmacol Exp Ther 330 1 (2009) 268-275
57. Bagnato A., and Rosano L. The endothelin axis in cancer. Int J Biochem Cell Biol 40 8 (2008) 1443-1451
58. Lalich M., McNeel D.G., Wilding G., and Liu G. Endothelin receptor antagonists in cancer therapy. Cancer Invest 25 8 (2007) 785-794
59. Carducci M.A., Saad F., Abrahamsson P.A., Dearnaley D.P., Schulman C.C., North S.A., et al. A phase 3 randomized controlled trial of the efficacy and safety of atrasentan in men with metastatic hormone-refractory prostate cancer. Cancer 110 9 (2007) 1959-1966
60. Nelson J.B., Love W., Chin J.L., Saad F., Schulman C.C., Sleep D.J., et al. Phase 3, randomized, controlled trial of atrasentan in patients with nonmetastatic, hormone-refractory prostate cancer. Cancer 113 9 (2008) 2478-2487
61. James N.D., Caty A., Borre M., Zonnenberg B.A., Beuzeboc P., Morris T., et al. Safety and efficacy of the specific endothelin-A receptor antagonist ZD4054 in patients with hormone-resistant prostate cancer and bone metastases who were pain free or mildly symptomatic: a double-blind, placebo-controlled, randomised, phase 2 trial. Eur Urol 55 5 (2009) 1112-1123